Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Pelthos Therapeutics (PTHS) Non-Current Assets (2025)

Pelthos Therapeutics has reported Non-Current Assets over the past 1 years, most recently at $77.0 million for Q4 2025.

For Q4 2025, Non-Current Assets changed N/A year-over-year to $77.0 million; the TTM value through Dec 2025 reached $153.7 million, changed N/A, while the annual FY2025 figure was $77.0 million, N/A changed from the prior year.
Non-Current Assets for Q4 2025 was $77.0 million at Pelthos Therapeutics, roughly flat from $76.7 million in the prior quarter.
Over five years, Non-Current Assets peaked at $77.0 million in Q4 2025 and troughed at $76.7 million in Q3 2025.